Literature DB >> 1279598

Incidence and predictors of loss of pacing in the atrium in patients with sick sinus syndrome.

E B Sgarbossa1, S L Pinski, L W Castle, R G Trohman, J D Maloney.   

Abstract

Atrial and dual-chamber pacemakers may be associated with reduced morbidity in patients with the sick sinus syndrome (SSS). In some patients, however, subsequent development of chronic atrial fibrillation or atrial lead failure make long-term pacing in the atrium not feasible. We analyzed the incidence and predictors of loss of atrial pacing in 395 consecutive patients with SSS (376 with dual-chamber pacemakers and 19 with single-chamber atrial pacemakers). None of them was in established atrial fibrillation at time of implant. Patients were followed-up for 55 +/- 35 months. Actuarial survival of effective atrial pacing was 92.5% at 1 year, 85% at 5 years, and 76.5% at 10 years. Overall, 60 patients lost atrial pacing. The most frequent cause was the development of chronic atrial fibrillation (53 patients). By multivariate analysis (Cox proportional-hazards model), independent predictors of loss of pacing in the atrium were preimplant episodes of paroxysmal atrial fibrillation (PAF) lasting more than 1 hour (P < 0.001; hazard ratio (HR) = 4.3); prior history of PAF for more than 5 years (P < 0.001; HR = 2.67; and endocardial P wave < 2 mV (P = 0.014; HR = 1.96). In a subgroup of patients (n = 187) who had echocardiograms, a left atrium > 50 mm was also an independent predictor of loss of atrial pacing (P = 0.028; HR = 2.28).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1992        PMID: 1279598     DOI: 10.1111/j.1540-8159.1992.tb03020.x

Source DB:  PubMed          Journal:  Pacing Clin Electrophysiol        ISSN: 0147-8389            Impact factor:   1.976


  1 in total

1.  [Selection of the optimal pacemaker - Are age and secondary disease related health conditions significant?].

Authors:  G H von Knorre; W Voss; B Ismer; H Lüssow
Journal:  Herzschrittmacherther Elektrophysiol       Date:  1997-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.